Service definition and boundaries
Sleep scale assessment services select, license, configure, administer, quality-control, score, and interpret sleep-related clinical outcome assessments for a defined clinical trial or research question. The target may be insomnia symptoms, daytime sleepiness, perceived sleep quality, functional impact, treatment experience, or an observer's report. A sleep scale is not a uniform test: each instrument has its own concept of interest, respondent, recall period, response options, scoring rules, language versions, and context of use. The service therefore begins with a measurement problem, not with a preferred questionnaire or software catalogue.
This service is not a clinical diagnosis, a routine medical interview, authorization to administer a regulated psychological test, generic statistical outsourcing, or merely the sale of questionnaire software. It is distinct from the preceding PSG endpoint assessment service, which derives trial endpoints from polysomnography, and it does not assume the overall site-management responsibilities of the following entry. A questionnaire score may support an endpoint, screen, or description, but it cannot by itself confirm or exclude insomnia, obstructive sleep apnea, a hypersomnolence disorder, or a psychiatric condition unless the instrument is supported for that precise context and the protocol defines such use.
Measurement strategy and context of use
The project should define the concept to be measured, target population, disease stage, intervention, trial phase, languages and regions, setting, and decision purpose before selecting an instrument. The team should state whether information comes directly from the participant, a non-clinician observer, a clinician, or performance on a task, distinguishing patient-reported, observer-reported, clinician-reported, and performance outcomes. Instruments do not measure the same construct merely because their titles contain the word sleep, and proxy reporting must not replace a participant's own report of feelings or symptoms when the participant can respond reliably.
The protocol should prospectively connect each scale to a trial objective, primary or secondary endpoint position, assessment time, baseline definition, scoring method, and statistical estimand. It should also address how treatment discontinuation, rescue medication, hospitalization, or other intercurrent events affect the meaning of the outcome. A scale battery should not be expanded or reduced after data access simply because observed results are convenient. When scales are combined with sleep diaries, actigraphy, PSG, or biomarkers, the measurement layer and handling of disagreement should be stated; one method is not automatically the calibration standard for another.
Instrument selection and evidence review
Candidate instruments should first be examined for content validity in the intended context: whether their items are relevant, comprehensive, and understandable to the target population. The review can then address structural validity, internal consistency, test-retest reliability, measurement error, cross-cultural validity, construct validity, responsiveness, and interpretability. Evidence must match the actual version, language, age group, condition, respondent, and mode of administration. One high correlation, a favorable internal-consistency coefficient, frequent past use, or publication in a prominent journal does not establish fitness for a new trial purpose.
The selection report should compare recall periods, item burden, response options, floor and ceiling effects, acceptability, missingness patterns, and ability to detect change, while documenting rejected instruments and reasons. It should verify the copyright holder, license scope, fees, approved languages, official translations, scoring manual, and restrictions on modification. A questionnaire visible online or reproduced in an article is not necessarily free to copy, translate, shorten, or digitize. A regulatory compendium is a useful search starting point, but inclusion is not agency endorsement and does not establish that the measure should be a particular trial's primary endpoint.
Translation, electronic migration, and accessibility
Multilingual implementation should use authorized versions and pursue conceptual rather than word-for-word equivalence. Depending on the evidence already available, work may include forward and back translation, reconciliation, expert review, cognitive interviews with the target population, and proofreading of the final layout. Regional terminology, cultural differences, and items that resist equivalence should be documented. The existence of a translation does not prove suitability for another region, literacy level, or patient group. Pediatric, proxy, and accessible versions require separate respondent definitions and support; ad hoc interpreting cannot be pooled silently with a validated version.
Migration from paper to a phone, website, telephone system, or another electronic clinical outcome assessment platform should evaluate whether item display, pagination, scrolling, font, response action, reminders, skip logic, or device differences alter measurement. The system should use risk-proportionate validation for identity, timestamps, source records, audit trails, permissions, backup, recovery, offline synchronization, and version control. Participants and sites need population-appropriate training, technical support, and a controlled alternative path. Accessibility should address visual, auditory, motor, cognitive, and language needs without assistance that suggests an answer or changes an item's meaning.
Trial implementation and data quality
An operations manual should freeze the window, order, setting, independent-completion requirement, permitted assistance, reminder rules, handling of late and duplicate entries, and relationship to medication, shifts, travel, and sleep periods for each visit or daily assessment. Site personnel may clarify the process but must not paraphrase items, imply a desirable answer, or reconstruct the participant's memory. Training and, where appropriate, certification should cover version identification, standardized instructions, escalation of urgent signals, technical failures, and protocol deviations, with rehearsal and ongoing review used to maintain consistency.
Quality control should review completion, timestamps, implausibly rapid or invariant response patterns, out-of-window entries, duplicates, device time zones, unexpected proxy use, and site differences promptly, without editing values in the background to manufacture completeness. Late entries, omitted items, withdrawal, hospitalization, loss to follow-up, technical failure, and intercurrent events need distinct reason codes. Retrospective batch completion from memory and investigator guesses are unacceptable. If responses indicate self-harm, dangerous sleepiness, or another safety concern, a predefined route should bring the information promptly to the investigator rather than leaving it for end-stage data cleaning.
Scoring, analysis, and interpretation
Before database release, the project should lock the authorized scoring algorithm, reverse-coded items, subscales, minimum valid items, time windows, units, rounding, and missing-item rules, and verify programmed scoring with known test cases. The statistical analysis plan should align the estimand, analysis population, baseline adjustment, repeated measures, covariates, multiplicity, sensitivity analyses, and missing-data assumptions. A total score must not replace a prespecified subscale without justification, the most favorable time point must not be selected after inspection, and responder or meaningful-change thresholds must not be invented after treatment-group results are known.
Mean change in a population, a between-group difference, and meaningful within-person change answer different questions. Any threshold needs evidence for the target population, an anchor strategy, and an account of uncertainty; minimal detectable change, statistical significance, and clinical importance are not interchangeable. Disagreement between a scale and PSG, actigraphy, or a diary may reflect distinct constructs, windows, or errors and does not justify automatically deleting one result. Reports should show completion, reasons for missingness, distributions, estimates and intervals, prespecified sensitivity findings, and limitations, without turning association into causation or trial-level results into individual diagnostic advice.
Governance, privacy, and acceptance
Contracts should assign the sponsor, investigator, instrument owner, translation provider, electronic-system vendor, statistician, and assessment service explicit responsibility for licensing, configuration, training, hosting, safety escalation, scoring, blinding, and archiving. The provider should minimize identity and health data, apply role-based access, transmission and storage safeguards, logs, retention limits, cross-border controls, and incident response, and support lawful access, correction, or withdrawal. Outsourcing does not transfer the sponsor's or investigator's legal responsibilities, and automated scoring or generative tools still require validation, change control, and accountable human governance.
Acceptable deliverables can include a measurement strategy, evidence and license register, version and translation inventory, configuration specification, validation records, training materials, data dictionary, scoring specification, query and deviation rules, blinded quality reports, analysis outputs, and an archive package. Changes to items, wording, devices, algorithms, or vendors require a comparability assessment and controlled approval. Marketing must not call a scale universally valid or perfectly objective, claim that it replaces a sleep study, or guarantee trial success. Quality is demonstrated by a clear concept, fit-for-purpose tool, traceable process, honest treatment of missing data, and interpretation that stays within the evidence.